Manufacturing for originator molecules is restricted by regulations, but drug makers can exploit newer technologies for the manufacture of biosimilars.
Catherine Shaffer
Advertisement
Catherine Shaffer is a contributing writer to BioPharm International, cathshaffer@gmail.com.
Articles by Catherine Shaffer
A multi-pronged approach to raw materials testing can help mitigate the risk of future contamination events.
Advertisement
Latest Updated Articles
Ensuring the Biological Integrity of Raw MaterialsFebruary 1st 2017
Advertisement
Advertisement
Trending on BioPharm International
1
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
2
Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial
3
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
4
Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US
5